Home-based telerehabilitation for rural men on hormone therapy for metastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized interventional study will enroll men with prostate cancer on androgen deprivation therapy who live in rural areas, randomizing them to multimodal telerehabilitation delivered at home versus home exercise without the telehealth technology. The intervention uses remote supervision and digital tools to guide exercise and rehabilitation, with participants followed for six months. The team will compare quality of life and cancer-related symptoms between groups and assess feasibility and acceptance of the program. Enrollment and oversight are coordinated through the Huntsman Cancer Institute at the University of Utah.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 21 years or older
2. Confirmed diagnosis of prostate cancer
3. Men receiving standard-of-care ADT either for high-risk, locally advanced prostate cancer or as a part of multicomponent management of metastatic prostate cancer;
4. Residing in a rural community defined by the Rural-Urban Commuting Area (RUCA) codes from the Federal Office of Rural Health Policy (4 and higher).

Exclusion Criteria:

1. Have unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures.
2. Are engaged in a regular exercise rehabilitation program.
3. Have relocation plans within the next 6 months
4. Participate in another clinical trial related to prostate cancer or rehabilitation. The patients will also be required to have a working telephone line in their home or a cell phone.

Where it's running

• University of Utah Huntsman Cancer Institute
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Manish Kohli, MD — University of Utah
• Study coordinator: Manish Kohli, MD
• Email: Manish.Kohli@hci.utah.edu
• Phone: 801-646-4018

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

• Understanding how ADT for prostate cancer may raise blood pressure and whether nerves or kidneys are involved

  This study tests whether nervous system or kidney dysfunction contributes to high blood pressure in men receiving androgen deprivation therapy for prostate cancer.

  Recruiting Phase 4 Virginia Commonwealth University · Richmond, Virginia · NCT07848828

• JANX013 and JANX007 combo in advanced prostate cancer

  A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.

  Recruiting Phase 1 Janux Therapeutics · Nashville, Tennessee · NCT07813637

• Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

  This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07686016

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Actinium (225Ac) PSMA therapy for castration‑resistant prostate cancer after Lutetium

  This trial will test whether an injectable Actinium-225 PSMA treatment can control advanced prostate cancer in men whose disease progressed after Lutetium‑PSMA therapy.

  Recruiting Phase 1/2 University College, London · London · NCT07414940

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.